

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 10

PATENT NO. : 7,012,133

APPLICATION NO.: 08/963,656

ISSUE DATE : March 14, 2006

INVENTOR(S) : Craig J. Gerard et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<110> GERARD, CRAIG J.
GERARD, NORMA P.
MACKAY, CHARLES R.
PONATH, PAUL D.
POST, THEODORE W.
QIN, SHIXIN

<120> ANTIBODIES TO C-C CHEMOKINE RECEPTOR 3 PROTEIN

<130> 079259-0040

<140> 08/963,656

<141> 1997-11-03

<150> 08/720,565

<151> 1996-09-30

<150> PCT/US96/00608

<151> 1996-01-19

<150> 08/375,199

<151> 1995-01-19

<160> 18

<170> PatentIn version 3.5

MAILING ADDRESS OF SENDER (Please do not use customer number below):

McDermott Will & Emery
28 State Street
Boston, MA 02109

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<210> 1
 <211> 1689
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> modified_base
 <222> (1291)..(1291)
 <223> a, c, t, g, unknown or other
 <400> 1

aatccctttc ctggcacctc tgatatacctt ttgaaattca tgtaaaagaa	tccctaggct	60
gctatcacat gtggcatctt tggtagtac atgaataaaat caactgggt	gttttacgaa	120
ggatgattat gcttcattgt gggattgtat ttttcttctt ctatcacagg	gagaagtgaa	180
atgacaacct cactagatac agttgagacc tttggatcca catcctacta	tgatgacgtg	240
ggctgtctct gtgaaaaaagc tgataccaga gcactgatgg cccagttgt	gcccccgtg	300
tactccctgg tggtaactgt gggcctctt ggcaatgtgg tgggtgtat	gatcctata	360
aaatacagga ggctccaat tatgaccaac atctacctgc tcaacctggc	catttggac	420
ctgctcttcc tcgtcacccct tccattctgg atccactatg tcagggggca	taactgggtt	480
tttggccatg gcatgtgtaa gtcctctca gggtttattc acacaggctt	gtacagcgag	540
atcttttca taatcctgct gacaatcgac aggtacctgg ccattgtcca	tgctgtgtt	600
gcccttcgag cccggactgt cacttttggt gtcatcacca gcatcgtcac	ctggggctg	660
gcagtgttag cagctttcc tgaatttattc ttctatgaga ctgaagagg	tttgaagag	720
actctttgca gtgctcttta cccagaggat acagtatata gctggaggca	tttccacact	780
ctgagaatga ccatcttctg ttcgttctc cctctgtcg ttatggccat	ctgctacaca	840
ggaatcatca aaacgctgct gaggtgcccc agtaaaaaaaa agtacaaggc	catccggctc	900
attttgtca tcatggcggt gtttttattt ttctgacac cctacaatgt	ggctatcctt	960
ctctcttcct atcaatccat ctatatttgg aatgactgtg agcggacgaa	gcatctggac	1020
ctggcatgc tggtagacaga ggtgatcgcc tactccact gtcatgaa	cccgtgtac	1080
tacgcctttg ttggagagag gttccggaaag tacctgcgccc acttcttcca	caggacttg	1140
ctcatgcacc tggcgagata catcccattc cttccttagt agaagctgaa	aagaaccagc	1200
tctgtctctc catccacagc agagccggaa ctctcttattt tgtttttagt	agatgcagaa	1260
aattgcctaa agaggaagga ccaaggagat naagcaaaca cattaagcct	tccacactca	1320
cctctaaaac agtccttcaa accttccagt gcaacactga agctcttaag	acactgaaat	1380
atacacacag cagtagcagt agatgcatgt accctaaggat cattaccaca	ggccagggt	1440
gggcagcgta ctcatcatca acctaaaaag cagagtttg cttctctctc	taaaatgagt	1500
tacatatatt ttaatgcacc tgaatgttag atagttacta tatgccgcta	caaaaaggta	1560
aaactttta tattttatac attaacttca gccagctatt atataaataa aacattttca		1620
cacaatacaa taagttact atttttattt ctaatgtgcc tagttcttc cctgcttaat		1680
gaaaagctt		1689

<210> 2
 <211> 355
 <212> PRT
 <213> Homo sapiens
 <400> 2

Met	Thr	Thr	Ser	Leu	Asp	Thr	Val	Glu	Thr	Phe	Gly	Thr	Thr	Ser	Tyr				
1								5					10		15				
Tyr	Asp	Asp	Val	Gly	Leu	Leu	Cys	Glu	Lys	Ala	Asp	Thr	Arg	Ala	Leu				
													20		25		30		
Met	Ala	Gln	Phe	Val	Pro	Pro	Leu	Tyr	Ser	Leu	Val	Phe	Thr	Val	Gly				
													35		40		45		
Leu	Leu	Gly	Asn	Val	Val	Val	Met	Ile	Leu	Ile	Lys	Tyr	Arg	Arg					
													50		55		60		
Leu	Arg	Ile	Met	Thr	Asn	Ile	Tyr	Leu	Leu	Asn	Leu	Ala	Ile	Ser	Asp				
													65		70		75		80
Leu	Leu	Phe	Leu	Val	Thr	Leu	Pro	Phe	Trp	Ile	His	Tyr	Val	Arg	Gly				
													85		90		95		
His	Asn	Trp	Val	Phe	Gly	His	Gly	Met	Cys	Lys	Leu	Leu	Ser	Gly	Phe				
													100		105		110		
Tyr	His	Thr	Gly	Leu	Tyr	Ser	Glu	Ile	Phe	Phe	Ile	Ile	Leu	Leu	Thr				
													115		120		125		
Ile	Asp	Arg	Tyr	Leu	Ala	Ile	Val	His	Ala	Val	Phe	Ala	Leu	Arg	Ala				

130	135	140
Arg Thr Val Thr Phe Gly Val Ile Thr Ser Ile Val Thr Trp Gly Leu		
145	150	155
Ala Val Leu Ala Ala Leu Pro Glu Phe Ile Phe Tyr Glu Thr Glu Glu		160
165	170	175
Leu Phe Glu Glu Thr Leu Cys Ser Ala Leu Tyr Pro Glu Asp Thr Val		
180	185	190
Tyr Ser Trp Arg His Phe His Thr Leu Arg Met Thr Ile Phe Cys Leu		
195	200	205
Val Leu Pro Leu Leu Val Met Ala Ile Cys Tyr Thr Gly Ile Ile Lys		
210	215	220
Thr Leu Leu Arg Cys Pro Ser Lys Lys Tyr Lys Ala Ile Arg Leu		
225	230	235
Ile Phe Val Ile Met Ala Val Phe Phe Ile Phe Trp Thr Pro Tyr Asn		240
245	250	255
Val Ala Ile Leu Leu Ser Ser Tyr Gln Ser Ile Leu Phe Gly Asn Asp		
260	265	270
Cys Glu Arg Thr Lys His Leu Asp Leu Val Met Leu Val Thr Glu Val		
275	280	285
Ile Ala Tyr Ser His Cys Cys Met Asn Pro Val Ile Tyr Ala Phe Val		
290	295	300
Gly Glu Arg Phe Arg Lys Tyr Leu Arg His Phe Phe His Arg His Leu		
305	310	315
Leu Met His Leu Gly Arg Tyr Ile Pro Phe Leu Pro Ser Glu Lys Leu		320
325	330	335
Glu Arg Thr Ser Ser Val Ser Pro Ser Thr Ala Glu Pro Glu Leu Ser		
340	345	350
Ile Val Phe		
355		

<210> 3
<211> 1193
<212> DNA
<213> Homo sapiens
<220>
<221> CDS
<222> (92)..(1156)
<400> 3

tttgtgcttat ccgggcagaacttatcgaa atacaataga agacccacgc gtccgggttt	60	
tacttagaag agattttcag ggagaagtga a atg aca acc tca cta gat aca	112	
Met Thr Thr Ser Leu Asp Thr		
1	5	
gtt gag acc ttt ggt acc aca tcc tac tat gat gac gtg ggc ctg ctc	160	
Val Glu Thr Phe Gly Thr Thr Ser Tyr Tyr Asp Asp Val Gly Leu Leu		
10	15	20
tgt gaa aaa gct gat acc aca gca ctg atg gcc cag ttt gtg ccc ccg	208	
Cys Glu Lys Ala Asp Thr Arg Ala Leu Met Ala Gln Phe Val Pro Pro		
25	30	35
ctg tac tcc ctg gtg ttc act gtg ggc ctc ttg ggc aat gtg gtg gtg	256	
Leu Tyr Ser Leu Val Phe Thr Val Gly Leu Leu Gly Asn Val Val Val		
40	45	50
gtg atg atc ctc ata aaa tac agg agg ctc cga att atg acc aac atc	304	
Val Met Ile Leu Ile Lys Tyr Arg Arg Leu Arg Ile Met Thr Asn Ile		
60	65	70
tac ctg ctc aac ctg gcc att tcg gac ctg ctc ctc gtc acc ctt	352	
Tyr Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Val Thr Leu		
75	80	85
cca ttc tgg atc cac tat gtc agg ggg cat aac tgg gtt ttt ggc cat	400	
Pro Phe Trp Ile His Tyr Val Arg Gly His Asn Trp Val Phe Gly His		
90	95	100
ggc atg tgt aag ctc ctc tca ggg ttt tat cac aca ggc ttg tac agc	448	

Gly	Met	Cys	Lys	Leu	Leu	Ser	Gly	Phe	Tyr	His	Thr	Gly	Leu	Tyr	Ser
105				110						115					
gag	atc	ttt	ttc	ata	atc	ctg	ctg	aca	atc	gac	agg	tac	ctg	gcc	att
Glu	Ile	Phe	Phe	Ile	Ile	Leu	Leu	Thr	Ile	Asp	Arg	Tyr	Leu	Ala	Ile
120				125					130				135		
gtc	cat	gct	gtg	ttt	gcc	ctt	cga	gcc	cgg	act	gtc	act	ttt	ggt	gtc
Val	His	Ala	Val	Phe	Ala	Leu	Arg	Ala	Arg	Thr	Val	Thr	Phe	Gly	Val
										140	145		150		
atc	acc	agc	atc	gtc	acc	tgg	ggc	ctg	gca	gtg	cta	gca	gct	ctt	cct
Ile	Thr	Ser	Ile	Val	Thr	Trp	Gly	Leu	Ala	Val	Leu	Ala	Ala	Leu	Pro
									155	160		165			
gaa	ttt	atc	ttc	tat	gag	act	gaa	gag	ttg	ttt	gaa	gag	act	ctt	tgc
Glu	Phe	Ile	Phe	Tyr	Glu	Thr	Leu	Cys							
					170		175			180					
agt	gct	ctt	tac	cca	gag	gat	aca	gta	tat	agc	tgg	agg	cat	ttc	cac
Ser	Ala	Leu	Tyr	Pro	Glu	Asp	Thr	Val	Tyr	Ser	Trp	Arg	His	Phe	His
					185		190			195					
act	ctg	aga	atg	acc	atc	ttc	tgt	ctc	gtt	ctc	cct	ctg	ctc	gtt	atg
Thr	Leu	Arg	Met	Thr	Ile	Phe	Cys	Leu	Val	Leu	Pro	Leu	Leu	Val	Met
					200		205			210		215			
gcc	atc	tgc	tac	aca	gga	atc	atc	aaa	acg	ctg	ctg	agg	tgc	ccc	agt
Ala	Ile	Cys	Tyr	Thr	Gly	Ile	Ile	Lys	Thr	Leu	Leu	Arg	Cys	Pro	Ser
					220		225			230					
aaa	aaa	aag	tac	aag	gcc	atc	cg	ctt	gtc	atc	atg	g	cg	gt	
Lys	Lys	Tyr	Lys	Ala	Ile	Arg	Leu	Ile	Phe	Val	Ile	Met	Ala	Val	
					235		240			245					
ttt	ttc	att	ttc	tgg	aca	ccc	tac	aat	gtg	gct	atc	ctt	ctc	tct	tcc
Phe	Phe	Ile	Phe	Trp	Thr	Pro	Tyr	Asn	Val	Ala	Ile	Leu	Leu	Ser	Ser
					250		255			260					
tat	caa	tcc	atc	tta	ttt	gga	aat	gac	tgt	gag	cg	agc	aag	cat	ctg
Tyr	Gln	Ser	Ile	Leu	Phe	Gly	Asn	Asp	Cys	Glu	Arg	Ser	Lys	His	Leu
					265		270			275					
gac	ctg	gtc	atg	ctg	gt	aca	gag	gt	atc	gcc	tac	tcc	cac	tgc	tgc
Asp	Leu	Val	Met	Leu	Val	Thr	Glu	Val	Ile	Ala	Tyr	Ser	His	Cys	Cys
					280		285			290		295			
atg	aac	ccg	gtg	atc	tac	gcc	ttt	gtt	gga	gag	agg	ttc	cg	aag	tac
Met	Asn	Pro	Val	Ile	Tyr	Ala	Phe	Val	Gly	Glu	Arg	Phe	Arg	Lys	Tyr
					300		305			310					
ctg	cgc	cac	tcc	cac	agg	cac	ttt	ctc	atg	cac	ctg	ggc	aga	tac	
Leu	Arg	His	Phe	His	Arg	His	Leu	Leu	Met	His	Leu	Gly	Arg	Tyr	
					315		320			325					
atc	cca	tcc	ttt	cct	agt	gag	aag	ctg	gaa	aga	acc	agc	tct	gtc	tct
Ile	Pro	Phe	Leu	Pro	Ser	Glu	Lys	Leu	Glu	Arg	Thr	Ser	Ser	Val	Ser
					330		335			340					
cca	tcc	aca	gca	gag	ccg	gaa	ctc	tct	att	gtg	ttt	taggttagatg			
Pro	Ser	Thr	Ala	Glu	Pro	Glu	Leu	Ser	Ile	Val	Phe				
					345		350			355					
cagaaaaattg	cctaaagagg	aaggacc													1193

<210> 4

<211> 355

<212> PRT

<213> Homo sapiens

<400> 4

Met Thr Thr Ser Leu Asp Thr Val Glu Thr Phe Gly Thr Thr Ser Tyr

1 5 10 15

Tyr Asp Asp Val Gly Leu Leu Cys Glu Lys Ala Asp Thr Arg Ala Leu

20 25 30

Met Ala Gln Phe Val Pro Pro Leu Tyr Ser Leu Val Phe Thr Val Gly

35 40 45

Leu Leu Gly Asn Val Val Val Met Ile Leu Ile Lys Tyr Arg Arg

50	55	60
Leu Arg Ile Met Thr Asn Ile Tyr	Leu Leu Asn	Leu Ala Ile Ser Asp
65	70	75
Leu Leu Phe Leu Val Thr Leu Pro Phe Trp	Ile His Tyr Val Arg Gly	80
85	90	95
His Asn Trp Val Phe Gly His Gly Met Cys Lys	Leu Leu Ser Gly Phe	
100	105	110
Tyr His Thr Gly Leu Tyr Ser Glu Ile Phe Phe	Ile Ile Leu Leu Thr	
115	120	125
Ile Asp Arg Tyr Leu Ala Ile Val His Ala Val	Phe Ala Leu Arg Ala	
130	135	140
Arg Thr Val Thr Phe Gly Val Ile Thr Ser Ile	Val Thr Trp Gly Leu	
145	150	155
Ala Val Leu Ala Ala Leu Pro Glu Phe Ile Phe	Tyr Glu Thr Glu Glu	160
165	170	175
Leu Phe Glu Glu Thr Leu Cys Ser Ala Leu Tyr	Pro Glu Asp Thr Val	
180	185	190
Tyr Ser Trp Arg His Phe His Thr Leu Arg Met	Thr Ile Phe Cys Leu	
195	200	205
Val Leu Pro Leu Leu Val Met Ala Ile Cys Tyr	Thr Gly Ile Ile Lys	
210	215	220
Thr Leu Leu Arg Cys Pro Ser Lys Lys Lys	Tyr Lys Ala Ile Arg Leu	
225	230	235
Ile Phe Val Ile Met Ala Val Phe Phe Ile Phe	Trp Thr Pro Tyr Asn	240
245	250	255
Val Ala Ile Leu Leu Ser Ser Tyr Gln Ser Ile	Leu Phe Gly Asn Asp	
260	265	270
Cys Glu Arg Ser Lys His Leu Asp Leu Val Met	Leu Val Thr Glu Val	
275	280	285
Ile Ala Tyr Ser His Cys Cys Met Asn Pro Val	Ile Tyr Ala Phe Val	
290	295	300
Gly Glu Arg Phe Arg Lys Tyr Leu Arg His Phe	Phe His Arg His Leu	
305	310	315
Leu Met His Leu Gly Arg Tyr Ile Pro Phe Leu	Pro Ser Glu Lys Leu	320
325	330	335
Glu Arg Thr Ser Ser Val Ser Pro Ser Thr Ala	Glu Pro Glu Leu Ser	
340	345	350
Ile Val Phe		
355		

<210>	5					
<211>	1116					
<212>	DNA					
<213>	Artificial Sequence					
<220>						
<223>	Description of Artificial Sequence: Synthetic					
	consensus sequence					
<400>	5					
cagggagaag	tgaaatgaca	acctcaactag	atacagtta	gaccttttgtt	accacatcct	60
actatgtga	cgtggccctg	ctctgtaaaa	aagctgatac	cagagcactg	atggcccagt	120
tttgtcccccc	gctgtactcc	ctgggtttca	ctgtgggcct	cttggggcaat	gtgggttgtgg	180
tgatgatcct	cataaaaatac	aggaggctcc	gaattatgac	caacatctac	ctgctcaacc	240
tggcatttc	ggacctgtc	ttcctcgta	cccttcatt	ctggatccac	tatgtcaggg	300
ggcataactg	ggtttttggc	catggcatgt	gtaagctcct	ctcagggttt	tatcacacag	360
gcttgtag	cgagatctt	ttcataatcc	tgctgacaat	cgacaggtac	ctggccattg	420
tccatgctgt	gtttgccctt	cgagccccgga	ctgtcactt	tgtgtcattc	accagcatcg	480
tcacctgggg	cctggcagtg	ctagcagctc	ttcctgaatt	tatcttctat	gagactgaag	540
agttgttga	agagactmtt	tgcagtgtc	tttaccaga	ggatacagta	tatagtgg	600
gssatttcca	cactctgaga	atgaccatct	tctgtctcg	tctccctctg	ctcgatcg	660
ccatctgcta	cacaggaatc	atcaaaacgc	tgctgaggtg	ccccagtaaa	aaaaagtaca	720
aggccatccg	gctcattttt	gtcatcatgg	cggtgtttt	cattttctgg	acaccctaca	780

atgtggctat ctttctctct tscywwymaw ycatcttatt tgaaaatgac tgtgagcggm
 mgarsmwyyk ggacctggtc atgctggta cagaggtgat cgccctactcc cactgctgca
 tgaaccgggt gatctacgcc tttgttggag agaggttccg gaagtacctg cgccacttst
 tccacaggca cttgctcatg cacctggca gatacatccc attccttcct agtgagaagc
 tggaaagaac cagctctgtc tctccatcca cagcagagcc ggaactctct attgtgtttt
 aggttagatgc agaaaaattgc ctaaagagga aggacc

<210> 6
 <211> 355
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 consensus sequence
 <220>
 <221> MOD_RES
 <222> (182)..(182)
 <223> Any amino acid
 <220>
 <221> MOD_RES
 <222> (196)..(197)
 <223> Any amino acid
 <220>
 <221> MOD_RES
 <222> (263)..(266)
 <223> Any amino acid
 <220>
 <221> MOD_RES
 <222> (276)..(279)
 <223> Any amino acid
 <220>
 <221> MOD_RES
 <222> (315)..(315)
 <223> Any amino acid
 <400> 6
 Met Thr Thr Ser Leu Asp Thr Val Glu Thr Phe Gly Thr Thr Ser Tyr
 1 5 10 15
 Tyr Asp Asp Val Gly Leu Leu Cys Glu Lys Ala Asp Thr Arg Ala Leu
 20 25 30
 Met Ala Gln Phe Val Pro Pro Leu Tyr Ser Leu Val Phe Thr Val Gly
 35 40 45
 Leu Leu Gly Asn Val Val Val Met Ile Leu Ile Lys Tyr Arg Arg
 50 55 60
 Leu Arg Ile Met Thr Asn Ile Tyr Leu Leu Asn Leu Ala Ile Ser Asp
 65 70 75 80
 Leu Leu Phe Leu Val Thr Leu Pro Phe Trp Ile His Tyr Val Arg Gly
 85 90 95
 His Asn Trp Val Phe Gly His Gly Met Cys Lys Leu Leu Ser Gly Phe
 100 105 110
 Tyr His Thr Gly Leu Tyr Ser Glu Ile Phe Phe Ile Ile Leu Leu Thr
 115 120 125
 Ile Asp Arg Tyr Leu Ala Ile Val His Ala Val Phe Ala Leu Arg Ala
 130 135 140
 Arg Thr Val Thr Phe Gly Val Ile Thr Ser Ile Val Thr Trp Gly Leu
 145 150 155 160
 Ala Val Leu Ala Ala Leu Pro Glu Phe Ile Phe Tyr Glu Thr Glu Glu
 165 170 175
 Leu Phe Glu Glu Thr Xaa Cys Ser Ala Leu Tyr Pro Glu Asp Thr Val
 180 185 190
 Tyr Ser Trp Xaa Xaa Phe His Thr Leu Arg Met Thr Ile Phe Cys Leu
 195 200 205

Val Leu Pro Leu Leu Val Met Ala Ile Cys Tyr Thr Gly Ile Ile Lys
 210 215 220
 Thr Leu Leu Arg Cys Pro Ser Lys Lys Tyr Lys Ala Ile Arg Leu
 225 230 235 240
 Ile Phe Val Ile Met Ala Val Phe Phe Ile Phe Trp Thr Pro Tyr Asn
 245 250 255
 Val Ala Ile Leu Leu Ser Xaa Xaa Xaa Ile Leu Phe Gly Asn Asp
 260 265 270
 Cys Glu Arg Xaa Xaa Xaa Asp Leu Val Met Leu Val Thr Glu Val
 275 280 285
 Ile Ala Tyr Ser His Cys Cys Met Asn Pro Val Ile Tyr Ala Phe Val
 290 295 300
 Gly Glu Arg Phe Arg Lys Tyr Leu Arg His Xaa Phe His Arg His Leu
 305 310 315 320
 Leu Met His Leu Gly Arg Tyr Ile Pro Phe Leu Pro Ser Glu Lys Leu
 325 330 335
 Glu Arg Thr Ser Ser Val Ser Pro Ser Thr Ala Glu Pro Glu Leu Ser
 340 345 350
 Ile Val Phe
 355

<210> 7
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 primer
 <220>
 <221> modified_base
 <222> (19)..(19)
 <223> Inosine
 <220>
 <221> modified_base
 <222> (24)..(24)
 <223> Inosine
 <400> 7
 tacctgctsa acctggccnt ggcng 25

<210> 8
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 primer
 <220>
 <221> modified_base
 <222> (9)..(9)
 <223> Inosine
 <220>
 <221> modified_base
 <222> (14)..(14)
 <223> Inosine
 <400> 8
 acctggccnt ggcnacactm ctctt 25

<210> 9
 <211> 27
 <212> DNA
 <213> Artificial Sequence

```
<220>
<223> Description of Artificial Sequence: Synthetic
      primer
<220>
<221> modified_base
<222> (18)..(18)
<223> Inosine
<400> 9
gaccgytacc tggccatngt ccaygcc
```

27

```
<210> 10
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      primer
<220>
<221> modified_base
<222> (10)..(10)
<223> Inosine
<400> 10
ggcrtggacn atggccaggt arcggtc
```

27

```
<210> 11
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      primer
<220>
<221> modified_base
<222> (1)..(1)
<223> Inosine
<220>
<221> modified_base
<222> (6)..(6)
<223> Inosine
<220>
<221> modified_base
<222> (16)..(16)
<223> Inosine
<220>
<221> modified_base
<222> (18)..(18)
<223> Inosine
<400> 11
naccanrttg tagggnrncc armarag
```

27

```
<210> 12
<211> 28
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      primer
<220>
<221> modified_base
<222> (8)..(8)
<223> Inosine
```

<220>		
<221> modified_base		
<222> (10)..(10)		
<223> Inosine		
<220>		
<221> modified_base		
<222> (23)..(23)		
<223> Inosine		
<400> 12		
tgtagggnrn ccarmaragr agnargaa		28
<210> 13		
<211> 27		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Description of Artificial Sequence: Synthetic primer		
<220>		
<221> modified_base		
<222> (12)..(12)		
<223> Inosine		
<220>		
<221> modified_base		
<222> (15)..(16)		
<223> Inosine		
<400> 13		
gaaggcgtag ansanngggt tgasgca		27
<210> 14		
<211> 25		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Description of Artificial Sequence: Synthetic primer		
<220>		
<221> modified_base		
<222> (4)..(4)		
<223> Inosine		
<220>		
<221> modified_base		
<222> (7)..(8)		
<223> Inosine		
<400> 14		
agansanngg gttgasgcag cwgtg		25
<210> 15		
<211> 48		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Description of Artificial Sequence: Synthetic oligonucleotide		
<220>		
<221> CDS		
<222> (16)..(48)		
<400> 15		
aagcttccag cagcc atg gac tac aag gac gac gat gac aaa gaa ttc		
Met Asp Tyr Lys Asp Asp Asp Asp Lys Glu Phe		
1	5	10

<210> 16
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic peptide
<400> 16
Met Asp Tyr Lys Asp Asp Asp Lys Glu Phe
1 5 10

<210> 17
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic primer
<400> 17
ttaagaattc acaacccac tagatac

27

<210> 18
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic primer
<400> 18
catagtggat ccagaatg

18

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.